APSR2026-843

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP08-013
P68
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221264-46904-APSR-843_439699.pdf
Format: PDF Only
06. Tuberculosis
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Fikrie El Mujahid * Medical Faculty Universitas Indonesia - Persahabtan Hospital Pulmonology and Respiratory Medicine East Jakarta, Jakarta Indonesia
Fathiyah Isbaniah - Medical Faculty Universitas Indonesia - Persahabtan Hospital Pulmonology and Respiratory Medicine East Jakarta, Jakarta Indonesia
Prasenohadi - - Medical Faculty Universitas Indonesia - Persahabtan Hospital Pulmonology and Respiratory Medicine East Jakarta, Jakarta Indonesia
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Fikrie
El Mujahid
fikrheksian@gmail.com
+6285643561144
31-40
Indonesia
Original Research
Efficacy of N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Tuberculosis Patients: A Randomized Controlled Trial
Maximum 25 words
Abstract Content
Drug-induced liver injury (DILI) is a significant complication of anti-tuberculosis treatment (ATT) that often leads to treatment interruption. N-acetylcysteine (NAC) acts as a glutathione precursor that mitigates oxidative stress in hepatocytes. This study evaluated the efficacy of NAC as an adjuvant therapy by monitoring the recovery of biochemical markers, specifically SGOT, SGPT, and total bilirubin levels in TB-DILI subjects.
A randomized open-label clinical trial was conducted at Persahabatan Hospital, Jakarta. Six subjects were randomized into two groups: the intervention group (n=3) received oral NAC 600 mg twice daily for 7 days alongside standard care, and the control group (n=3) received standard care alone. Biochemical liver functions (SGOT, SGPT, and total bilirubin) were evaluated at baseline (D0), day 3 (D3), and day 6 (D6).
Six subjects were included in the final analysis. In the NAC group, a rapid and consistent decline in liver parameters was observed from D0 to D6. SGPT levels decreased from a baseline mean of 112.6 U/L to 33.6 U/L, and SGOT levels decreased from a mean of 161 U/L to 29.6 U/L. Significant improvement in total bilirubin was also noted in subjects with high baseline values (improving from a mean of 8.55 mg/dL to 2.17 mg/dL). In the control group, although liver enzymes also showed a downward trend, the D6 SGPT levels remained notably higher (mean 90 U/L) compared to the NAC group. No adverse events related to NAC administration were reported during the study.
N-acetylcysteine as an adjuvant therapy facilitates faster normalization of SGOT, SGPT, and total bilirubin levels in tuberculosis subjects with DILI. These findings suggest that NAC is a safe and effective adjunct to standard care in promoting accelerated liver recovery.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
N-acetylcysteine, drug-induced liver injury, liver enzymes
maximum 3 keywords and no abbreviations, separated by commas
 
291